Enalapril improves endothelial function in patients with migraine: A randomized, double-blind, placebo-controlled trial

Journal of Research in Medical Sciences

Volumn 16, Issue 1, 2011, Pages 26-32

  Javanmard, Shaghayegh Haghjooy ^a   Sonbolestan, Seyed Ali ^a   Ghahdarijani, Kian Heshmat ^a   Saadatnia, Mohamad ^b   Sonbolestan, Seyed Ahmad ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C Reactive Protein; Endothelium; Migraine Disorders; Nitrites

Indexed keywords

C REACTIVE PROTEIN; ENALAPRIL; NITRITE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MALE; MIGRAINE WITHOUT AURA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VASODILATATION;

EID: 79551710405     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med 2007;167(8):795-801.
2. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005;330(7482):63.
3. Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turhan H. Decreased endothelium-dependent vasodilatation in patients with migraine: a new aspect to vascular pathophysiology of migraine. Coron Artery Dis 2006;17(1):29-33.
4. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23(2):168-75.
5. Neutel JM. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004;18(9):599-606.
6. Ravandi A, Teo KK. Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Rev Cardiovasc Ther 2009;7(6):667-74.
7. Meier P, Maillard M, Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord 2005;5(1):15-30.
8. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006;24(1):11-25.
9. Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998;19 Suppl G:G48-53.
10. Enseleit F, Hürlimann D, Lüscher TF. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 2001;37 Suppl 1:S21-30.
11. Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents 2005;3(2):133-48.
12. Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother 2009;63(10):754-61.
13. Silva FA, Rueda-Clausen CF, Silva SY, Zarruk JG, Guzmán JC, Morillo CA, et al. Endothelial function in patients with migraine during the interictal period. Headache 2007;47(1):45-51.
14. de Hoon JN, Smits P, Troost J, Struijker-Boudier HA, Van Bortel LM. Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects. Cephalalgia 2006;26(1):56-63.
15. Rassaf T, Heiss C, Hendgen-Cotta U, Balzer J, Matern S, Kleinbongard P, et al. Plasma nitrite reserve and endothelial function in the human forearm circulation. Free Radic Biol Med 2006;41(2):295-301.
16. nd edition. Cephalalgia 2004;24 Suppl 1:9-160.
17. Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turhan H. Increased dilator response to nitrate and decreased flowmediated dilatation in migraineurs. Headache 2007;47(1):104-10.
18. Nagai T, Tabara Y, Igase M, Nakura J, Miki T, Kohara K. Migraine is associated with enhanced arterial stiffness. Hypertens Res 2007;30(7):577-83.
19. Tietjen GE, Al-Qasmi MM, Athanas K, Dafer RM, Khuder SA. Increased von Willebrand factor in migraine. Neurology 2001;57(2):334-6.
20. Tietjen GE, Al-Qasmi MM, Athanas K, Utley C, Herial NA. Altered hemostasis in migraineurs studied with a dynamic flow system. Thromb Res 2007;119(2):217-22.
21. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke 2009;40(9):2977-82.
22. Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN, et al. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 2008;70(17):1510-7.
23. Munakata M, Aihara A, Nunokawa T, Ito N, Imai Y, Ito S, et al. The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension--comparison with calcium channel blockers. Clin Exp Hypertens 2003;25(3):169-81.
24. Morawietz H, Rohrbach S, Rueckschloss U, Schellenberger E, Hakim K, Zerkowski HR, et al. Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy. Eur J Clin Invest 2006;36(10):705-12.
25. Cesari M, Kritchevsky SB, Atkinson HH, Penninx BW, Di Bari M, Tracy RP, et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J 2009;157(2):334.e1-8.
26. Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, Marini C, Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine. Cephalalgia 2003;23(1):39-42.
27. Kurth T, Ridker PM, Buring JE. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 2008;28(1):49-56.
28. de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, van Bortel LM. Cranial and peripheral interictal vascular changes in migraine patients. Cephalalgia 2003;23(2):96-104.
29. Bryan NS. Nitrite in nitric oxide biology: cause or consequence? A systems-based review. Free Radic Biol Med 2006;41(5):691-701.
30. van der Harst P, Asselbergs FW, Hillege HL, Voors AA, van Veldhuisen DJ, van Gilst WH. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. Am J Cardiol 2008;102(2):223-5.
31. Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story. Drugs 2009;69(3):265-77.
32. Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 2009;29(9):921-7.
33. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322(7277):19-22.